Biologics Approved In 2010
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Chart lists full licensing approvals for therapeutic biologics, imaging agents and vaccines. FDA transferred review of most therapeutic biologics to the Center for Drug Evaluation & Research on Oct. 1, 2003; products that continue to be reviewed by the Center for Biologics Evaluation & Research, including vaccines, cellular products, antitoxins and immunoglobulins, are designated with an asterisk (*). Diagnostics are not included.
You may also be interested in...
Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady
Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product